Tenax Therapeutics is trading 5% down at $2.02, with the decline appearing primarily linked to broader risk-off trading.
- Shares rose 7.58% to $2.13 on September 9.
- No new company-specific announcement was identified for September 10. The September 9 Cantor presentation renewed attention on LEVEL trial subgroup findings and the revised development strategy.
- Major indexes are down more than 0.5% as investors assess elevated inflation, firm yields, and geopolitical oil concerns.